$GKOS

Navratil Tomas sold $201K of GKOS

Navratil Tomas (CHIEF DEVELOPMENT OFFICER) sold 1,537 shares of GLAUKOS Corp (GKOS) at $130.68 ($0.20M total) on 2026-06-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Navratil Tomas
Published Jun 18, 2026, 11:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 11:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GKOS
Neutral
medium confidence
Mentioned
$GKOS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

The disclosed sale is a concrete, newly filed datapoint that can influence short-term sentiment, but the 10b5-1 structure generally limits inference about near-term fundamentals.

02

Market read

Traders may monitor GKOS for follow-on insider activity, but this specific filing alone is unlikely to drive a major repricing.

03

What to watch

The filing date may lag the actual sale; traders should avoid over-weighting the disclosure versus the execution date and consider whether there are concurrent insider buys/sales or upcoming company-specific events.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-18 after-hours; reflects sale executed 2026-06-16.

Background

This is an SEC Form 4 insider transaction disclosure for GLAUKOS Corp (GKOS) by an officer, including execution details and confirmation of a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$GKOSNeutralMedium confidence
Context

Form 4 shows GKOS chief development officer Navratil Tomas sold 1,537 shares for about $200,855 on 2026-06-16 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this disclosure; any reaction is likely muted and short-lived.

Evidence & confidence

The transaction is an open-market sale by an officer and explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No direct sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as a mild caution signal, especially if paired with other negative catalysts not mentioned here.

Key entities

  • GLAUKOS Corp

    Subject of the Form 4 insider transaction disclosure (GKOS).

  • Navratil Tomas

    Chief Development Officer who sold 1,537 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GKOSHighAI 8/10

Glaukos Market Cap More Than Doubles in a Year to $11B

Glaukos Corp.'s market cap has more than doubled to $11 billion in a year, driven by expanding into new eye care markets and record Q2 sales of $185.6 million. The company raised its full-year guidance and saw its shares rise over 15% post-earnings. Key products include iDose TR for glaucoma and Epioxa for keratoconus, with several other products in development.

$GKOSMed

GKOS Stock Surges 67% Year to Date: What's Driving the Rally?

Glaukos (GKOS) shares have risen 67.9% year-to-date, driven by strong revenue growth and product launches. Q2 revenue increased 49.5% to $185.6M, prompting raised 2026 guidance to $680-700M. Growth is attributed to iDose TR and Epioxa, with international expansion and a broad pipeline also contributing. Competitors include Alcon (ALC), Sight Sciences (SGHT), and AbbVie (ABBV). Risks include reimbursement and competition.

$GKOSMedAI 8/10

Glaukos Corp stock hits all-time high at 190.27 USD

Glaukos Corp (GKOS) hit an all-time high of $190.27, with a 111.6% increase over the past year. Its market cap is $11.03 billion, and revenue grew 41.55% over the last twelve months. Q2 2026 revenue was $185.6 million, up 49.5% year-over-year, exceeding estimates. Analysts raised price targets, with Truist Securities setting it at $215.

$GKOSMedAI 8/10

Glaukos (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.